Stay up to date! See our latest report based on 2023 sales: Top 20 Pharma and Biopharma Companies 2023.
Headquarters: Ingelheim, Germany
twitter.com/Boehringer
www.boehringer-ingelheim.com
Headcount: 53,155
Year Established: 1989
Revenues: $19,707 (+21%)
Net Income: $3,396 (+1%)
R&D: $5,388 (+22%)
In 2022, Boehringer-Ingelheim’s pharma revenue rose 21% to $19,707 million despite uncertainties such as Russia’s war in Ukraine, which caused rising energy prices, sharp increases in cost of living and geopolitical tensions. The company’s research focuses on cardiovascular and metabolic diseases, oncology, respiratory diseases, immunology, diseases of the central nervous system (CNS) and retinal health.
Jardiance, a medicine for treatment of type 2 diabetes that also reduces the risk of cardiovascular diseases for type 2 diabetics with pre-existing cardiovascular conditions, was the group’s best-selling Human Pharma product for the fourth consecutive year. In addition, in 2022, Jardiance was approved by the U.S (FDA) and the European (EMA) regulatory authorities for the treatment of heart failure with preserved ejection fraction.
Three other products also played a significant role in Boehringer Ingelheim’s success: Spirivia, which is used for the treatment of chronic obstructive pulmonary disease (COPD) as well as asthma, Trajenta, which is used for the treatment if type 2 diabetes, and Pradaxa, which is used to prevent strokes in patients with atrial fibrillation and for the prevention and treatment of thromboembolic disorders. Another milestone was reached in September 2022 with the approval of Spevigo (spesolimab) in Japan and the U.S. Spevigo is the first product to receive FDA approval for the treatment of generalized pustular psoriasis (GPP)—a rare, life-threatening neutrophilic disease.
Boehringer Ingelheim also launched several new partnerships and was able to strengthen its pipeline on this basis. For example, the company is working with Lifebit Biotech, a biomedical data analytics provider, to build a scalable data, analytics and infrastructure platform. The aim of this collaboration is to collect findings from large external biobanks, thereby accelerating the development of new drugs. Together with Evotec SE and bioMérieux, Boehringer Ingelheim also launched the company Aurobac Therapeutics SAS, which aims to develop novel antibiotic precision therapies to combat antimicrobial resistance.
A new grant program in partnership with the University of Tübingen, Germany, aims to explore new approaches to improving human and animal health through AI and data science methods. After the successful start of an initial joint development in 2020, the company also started another collaboration with Click Therapeutics to develop another digital health application for prescribing to patients with schizophrenia, which could be used alone or in combination with the drug therapy.
In April 2023, Boehringer Ingelheim inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riss, Germany. The new high-tech facility underlines the company’s strong commitment to Germany and Europe as location for research and development for the care of patients around the world. With the investment of $382 million, Boehringer Ingelheim significantly enhances its innovation power and development of biopharmaceutical development capabilities in Germany.
Most recently, in May 2023, Boehringer Ingelheim broke ground on a major investment of $313 million to build a new Chemical Innovation Plant at its headquarters in Ingelheim, Germany.